IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein

Less than a year after the global emergence of the coronavirus SARS-CoV-2, a novel vaccine platform based on mRNA technology was introduced to the market. Globally, around 13.38 billion COVID-19 vaccine doses of diverse platforms have been administered. To date, 72.3% of the total population has bee...

Descripción completa

Detalles Bibliográficos
Autores principales: Uversky, Vladimir N., Redwan, Elrashdy M., Makis, William, Rubio-Casillas, Alberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222767/
https://www.ncbi.nlm.nih.gov/pubmed/37243095
http://dx.doi.org/10.3390/vaccines11050991

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10222767/
https://www.ncbi.nlm.nih.gov/pubmed/37243095
http://dx.doi.org/10.3390/vaccines11050991

Ejemplares similares